New drug combo targets tough breast cancer

NCT ID NCT03109080

Completed Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the drug olaparib (a PARP inhibitor) given alongside radiation therapy for people with triple-negative breast cancer that is advanced or has come back. The main goal was to find the safest dose of olaparib when used with radiation, and to watch for side effects. 24 participants were enrolled to help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (a PARP inhibitor drug) combined with radiation therapy
What this could lead to: If successful, this could point toward a new treatment option for hard-to-treat triple-negative breast cancer by combining a targeted drug with radiation.
What could go wrong: This is an early Phase 1 trial with only 24 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM MALIGNANT FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer radiation injury triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM MALIGNANT FEMALE BREAST NEOPLASMS, TRIPLE-NEGATIVE RADIOTHERAPY SIDE EFFECT

Contacts and locations

Show contact details

Locations

Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.